Label: POLIFLEKS- 0.9% isotonic sodium chloride solution

  • NDC Code(s): 84879-263-01, 84879-263-02, 84879-263-03, 84879-263-04, view more
    84879-263-05
  • Packager: POLIFARMA ILAC SANAYI VE TICARET ANONIM SIRKETI CORLU SUBESI
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Unapproved drug for use in drug shortage

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated March 4, 2025

If you are a consumer or patient please visit this version.

  • HEALTH CARE PROVIDER LETTER

    [Text Box: Subject: Temporary Importation of 0.9% Sodium Chloride Injection Products from Turkey to address drug shortages.] February 21, 2025

    Dear Healthcare Provider,

    In order to address shortages of Sodium Chloride Injection, USP, in the United States, GLOBAL GUARD INC. is coordinating with the U.S. Food and Drug Administration (FDA) to temporarily import 0.9% Sodium Chloride Solution from POLIFARMA’s manufacturing facility in Turkey.


    FDA has not approved these products manufactured by Polifarma.

    You may be provided with additional letters for other imported products you receive. Please read each letter in its entirety because as each letter may contain different product-specific information.


    At this time, no other entity except Global Guard, Inc is authorized by the FDA to import or to distribute this Polifarma product in the United States.

    Effective immediately, and during this temporary period, Global Guard, Inc., will offer the following presentations of Polifarma POLİFLEKS® 0.9% Isotonic Sodium Chloride Solution:

    pnd

    It is important to note the following:

    The imported products do not have a UPC barcode on the bag, rather they have a GTIN barcode that contains the product Global Trade Identification Number (GTIN). The barcode on the imported product labels may not register accurately in U.S. scanning systems. Alternative procedures should be followed to ensure that the correct drug product is being used in all systems and processes and administered to individual patients. For example, institutions should consider manually inputting the product into their systems and ensure that barcode systems provide correct information when the product is scanned.

    These products are available only by prescription in the U.S. the imported products do not have the statement “Rx only” they state Sold with Prescription on the labeling.

    After opening the carton or box, the bags should be inspected visually to confirm there is no visible particulate matter or bag defects; such as, leaks. Container integrity is imperative to ensure sterility of products listed in Table 1. Parenteral drug products should be inspected visually for particulate matter and bag defects prior to administrations, whenever solution or container permits. This requirement is specifically stated on the package for the products which are subject to this notification.

    You should perform a visual inspection of the bag prior to administration of the solution.

    USE A NEW BAG IF PARTICULATES ARE VISIBLE OR IF THE IV BAG CONTAINS A LEAK

    Additional key differences in the labeling between the FDA-approved products and the imported products are stated in the product comparison tables at the end of this letter as follows:

    Table 1. Key differences between FDA-approved and imported 0.9% Sodium Chloride Injection USP

    Table 2. Label images of FDA-approved and imported 0.9% Sodium Chloride Injection USP

    Please refer to FDA-approved prescribing information as follows:

    0.9% Sodium Chloride Injection, USP, Polifleks Polypropylene I.V. bag (click here)

    Reporting Adverse Events:

    Healthcare providers should report adverse events associated with the use of POLİFLEKS 0.9% Isotonic Sodium Chloride Solution for I.V. Infusion to GLOBAL GUARD LLC by phone: 1-800-555-1212 NEED TO ESTABLISH # ; email: AER@GLOBALGUARDCORP.COM NEED TO ESTABLISH

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax:

    Complete and submit the report Online: www.fda.gov/medwatch/report.htm
    Regular Mail or Fax: Download form https://www.accessdata.fda.gov/scripts/medwatch/index.cfm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

    Please ensure that your staff and others in your institution who may be involved in the administration of POLİFLEKS 0.9% Isotonic Sodium Chloride Solution for I.V. Infusion receives a copy of this letter and reviews the information.

    To place an order:

    please contact GLOBAL GUARD LLC at orders@globalguardcorp.com

    For all other inquiries please contact GLOBAL GUARD LLC at 1-800-555-1212 (phone); email: INFO@GLOBALGUARDCORP.COM

    Gürmen Kaynar Michael Bogdan

    International Markets and President
    Business Development Director Global Guard LLC
    POLIFARMA İLAC SAN. ve TIC. A.Ş.

    Table 1. Key differences between FDA-approved and imported 0.9% Sodium Chloride Injection USP

    FDA approved product

    Imported product from Turkey

    Product name

    Sodium Chloride Injection, USP

    in VIAFLEX Plastic Container

    POLİFLEKS 0.9% Isotonic Sodium Chloride Solution for I.V. Infusion

    Label volume

    1,000 mL

    1,000 mL

    Language of the labels

    English

    English

    Indications

    Sodium Chloride Injection, USP is indicated as a source of water and electrolytes. 0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.

    POLİFLEKS 0.9% ISOTONIC SODIUM CHLORIDE is indicated in the following situations:

    - Treatment of isotonic extracellular dehydration

    - Treatment of sodium depletion

    - As diluent of compatible drugs for parenteral administration.

    Active Ingredients

    Each 100 ml contains 900 mg Sodium Chloride, USP

    Each 100 ml contains 900 mg Sodium Chloride

    Additional Information

    pH is 5.0 (4.5 to 7.0) Osmolarity 308 mOsm/L (calc)

    pH is 5.5 (4.5 – 7.0). Osmolarity of solution is 308 mOsmol/l.

    Storage conditions

    Store at room temperature 25 ° C/77° F.

    Store at room temperature below 25°C.

    Container type

    VIAFLEX PVC

    POLIFLEKS POLYPROPYLENE

    Medication and administration port closures

    Contains medication port and administration port; Pull off port protector (blue color), right side

    Contains medication port and administration port; Pull off port protector (CLEAR/no color), right side

    [A close-up of a plastic tube Description generated with high confidence]

    Table 2. Label images of FDA-approved and imported 0.9% Sodium Chloride Injections

    FDA approved product

    Imported product from Turkey

    0.9% Sodium Chloride Injection USP

    0.9% ISOTONIC SODIUM CHLORIDE SOLUTION

    Label Color: Black barcode not shown

    1,000 mL shown as representative label

    Label: Color Black barcode shown 1000 mL shown as representative label

  • PRINCIPAL DISPLAY PANEL

    50mL

    250ml

    500mL

    1000 mL

    3000 mL

  • INGREDIENTS AND APPEARANCE
    POLIFLEKS 
    0.9% isotonic sodium chloride solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:84879-263
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ISOTONIC SODIUM CHLORIDE SOLUTION (UNII: VR5Y7PDT5W) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CATION0.9 g  in 100 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:84879-263-0150 mL in 1 BAG; Type 0: Not a Combination Product03/10/2025
    2NDC:84879-263-02250 mL in 1 BAG; Type 0: Not a Combination Product03/10/2025
    3NDC:84879-263-03500 mL in 1 BAG; Type 0: Not a Combination Product03/10/2025
    4NDC:84879-263-041000 mL in 1 BAG; Type 0: Not a Combination Product03/10/2025
    5NDC:84879-263-053000 mL in 1 BAG; Type 0: Not a Combination Product03/10/2025
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug for use in drug shortage03/10/2025
    Labeler - POLIFARMA ILAC SANAYI VE TICARET ANONIM SIRKETI CORLU SUBESI (751139942)
    Establishment
    NameAddressID/FEIBusiness Operations
    POLIFARMA ILAC SANAYI VE TICARET ANONIM SIRKETI CORLU SUBESI751139942analysis(84879-263) , label(84879-263) , manufacture(84879-263) , pack(84879-263) , sterilize(84879-263)